<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The records of 49 patients with nodular histiocytic <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (NH) who were treated from 1972 to 1985 in hospitals belonging to the JLRTG were retrospectively reviewed </plain></SENT>
<SENT sid="1" pm="."><plain>The actuarial survival rate and relapse-free survival rate of <z:hpo ids='HP_0000001'>all</z:hpo> patients after 5 years were 55.0 and 51.3%, respectively </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty-one patients with stage I disease had a significantly better survival rate than did 12 patients with stage II disease (P less than 0.01) </plain></SENT>
<SENT sid="3" pm="."><plain>Without combination chemotherapy, <z:hpo ids='HP_0000001'>all</z:hpo> 15 patients with stage I NH treated by radiation therapy were in complete remission, and 14 of them remained alive and well </plain></SENT>
<SENT sid="4" pm="."><plain>Among these 15 patients, no difference in relapse was observed between patients who received involved field irradiation (1 of 6) and those who received extended field irradiation (2 of 9) </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with stage II or more NH should be treated with intensive chemotherapy and radiotherapy, as are patients with diffuse histiocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (DH) </plain></SENT>
<SENT sid="6" pm="."><plain>However, involved field radiotherapy with careful follow-up observation may be the treatment of choice for patients with stage I NH, provided their <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> are not bulky </plain></SENT>
</text></document>